The panelists close their discussion on non-small cell lung cancer by emphasizing the need for continued research, early screening, and collaboration with dermatologists to address the unmet needs and improve overall outcomes.
Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Experts discuss the process of assessing decision-making capacity in patients with cancer.
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.
In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.
The relatively inexpensive nature of liquid biopsy may allow for more frequent screening among individuals who are at risk of developing pancreatic cancer.
Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
Investigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
The clinical investigator and her colleagues sought to evaluate differences in baseline characteristics, treatment patterns, and survival outcomes in diabetic versus nondiabetic patients enrolled in the CONNECT Multiple Myeloma Registry.
In this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.
Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.
Panelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
The panelists close by emphasizing key takeaways regarding the management of HER2+ colorectal cancer, including early molecular profiling to enable targeted therapy sequencing, assessing HER2 amplification level, and having a strategic plan upfront mapping out potential targeted therapy options rather than just starting chemotherapy.
Experts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.
Conclusion of the discussion and award presentation.